GLUE

Monte Rosa Therapeutics Inc

GLUE, USA

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

https://www.monterosatx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GLUE
stock
GLUE

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry Sahm

Read more →
GLUE
stock
GLUE

'Stick and glue' method enables more precise biomolecule tracking in cells Phys.org

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$17.2

Analyst Picks

Strong Buy

6

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

50.53

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

5.54

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-11.02 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-5.89 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

781.46 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

0.87

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 119.94% of the total shares of Monte Rosa Therapeutics Inc

1.

NEA Management Company, LLC

(12.4553%)

since

2025/06/30

2.

T. Rowe Price Associates, Inc.

(10.2424%)

since

2025/06/30

3.

Bvf Inc

(9.1648%)

since

2025/06/30

4.

Versant Venture Management LLC

(9.1531%)

since

2025/06/30

5.

Baker Bros Advisors LP

(7.9601%)

since

2025/06/30

6.

BlackRock Inc

(6.2281%)

since

2025/06/30

7.

venBio Select Advisor LLC

(6.0315%)

since

2025/06/30

8.

Suvretta Capital Management, LLC

(5.4405%)

since

2025/06/30

9.

Vanguard Group Inc

(5.0851%)

since

2025/06/30

10.

US Small-Cap Growth II Equity Comp

(4.7198%)

since

2025/06/30

11.

T. Rowe Price New Horizons

(4.594%)

since

2025/07/31

12.

FMR Inc

(3.7048%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(3.0439%)

since

2025/07/31

14.

Aisling Capital Management LP

(2.384%)

since

2025/06/30

15.

Alphabet Inc

(2.3705%)

since

2025/06/30

16.

HBM Healthcare Investments AG Ord

(2.2783%)

since

2025/06/30

17.

AQR Capital Management LLC

(2.0789%)

since

2025/06/30

18.

FIAM Small Cap Core CIT Cl B

(2.0375%)

since

2025/06/30

19.

Geode Capital Management, LLC

(1.8202%)

since

2025/06/30

20.

iShares Russell 2000 ETF

(1.7814%)

since

2025/08/31

21.

T. Rowe Price Health Sciences

(1.688%)

since

2025/07/31

22.

T. Rowe Price New Horizons Tr-A

(1.4607%)

since

2025/06/30

23.

State Street Corp

(1.3469%)

since

2025/06/30

24.

Northern Trust Corp

(1.2329%)

since

2025/06/30

25.

Parkwood LLC

(1.1464%)

since

2025/06/30

26.

Renaissance Technologies Corp

(0.996%)

since

2025/06/30

27.

Morgan Stanley - Brokerage Accounts

(0.9237%)

since

2025/06/30

28.

T. Rowe Price Integrated US Sm Gr Eq

(0.8686%)

since

2025/07/31

29.

T. Rowe Price Integrated US SmCapGrEq

(0.8686%)

since

2025/06/30

30.

Strategic Advisers Fidelity US TtlStk

(0.8153%)

since

2025/07/31

31.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7912%)

since

2025/07/31

32.

Royal Bank of Canada

(0.7607%)

since

2025/06/30

33.

Fidelity Small Cap Index

(0.758%)

since

2025/06/30

34.

Fidelity Series Small Cap Core

(0.6772%)

since

2025/06/30

35.

iShares Russell 2000 Value ETF

(0.655%)

since

2025/08/31

36.

Avantis US Small Cap Value ETF

(0.5281%)

since

2025/08/30

37.

NT Quality Small Cap Value

(0.5101%)

since

2025/06/30

38.

Northern Small Cap Value

(0.5101%)

since

2025/06/30

39.

iShares Biotechnology ETF

(0.4398%)

since

2025/08/31

40.

Fidelity Extended Market Index

(0.3871%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1598

Latest Release

Date

2025-09-30

EPS Actual

-0.33

EPS Estimate

-0.36

EPS Difference

0.03

Surprise Percent

8.3333%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Strong Momentum(7)
Net Net
Possible Net-Net(4)
Quality
Moderate Quality(4)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.